Core Viewpoint - Medtronic plc (NYSE:MDT) has seen a 12.9% increase in its share price over the past year, with analysts expressing mixed views on its future performance amid macroeconomic challenges [2]. Analyst Ratings and Price Targets - Truist maintained a Hold rating on Medtronic and reduced the price target from $110 to $107, citing potential macroeconomic headwinds affecting near-term valuation [2]. - Stifel also kept a Hold rating with a price target of $105, following the FDA's approval of Medtronic's HUGO platform, which is expected to enhance its position in the competitive US surgical market [2]. - William Blair upgraded Medtronic to Outperform from Market Perform, anticipating high single-digit earnings per share growth, while Piper Sandler maintained a Neutral rating with a $105 price target [2]. Upcoming Financial Performance - Jim Cramer indicated that Medtronic is expected to report better than anticipated financial results in the near future [3].